(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The "Autoimmune Collaboration and Licensing Deals 2016-2025" has been added to ResearchAndMarkets's offering.
Fully revised and updated, the report provides details of 943 autoimmune deals from 2016 to 2025.

Autoimmune Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the autoimmune deals entered into by the world's leading biopharma companies. The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters provide an orientation of autoimmune dealmaking and business activities. The report includes an introduction, an analysis of the trends in autoimmune dealmaking, financial deal terms including stage of development, a review of the top 25 most active biopharma companies, and a detailed directory of autoimmune deals by therapeutic target. Links to online contract documents are provided where available, offering comprehensive insights into each agreement.
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in autoimmune dealmaking
2.1. Introduction
2.2. Autoimmune deals over the years
2.3. Autoimmune deals by deal type
2.4. Autoimmune deals by industry sector
2.5. Autoimmune deals by stage of development
2.6. Autoimmune deals by technology type
Chapter 3 - Financial deal terms for autoimmune deals
3.1. Introduction
3.2. Disclosed financials terms for autoimmune deals
3.3. Autoimmune deal headline values
3.4. Autoimmune deal upfront payments
3.5. Autoimmune deal milestone payments
3.6. Autoimmune deal royalty rates
Chapter 4 - Leading autoimmune dealmakers and deals
4.1. Introduction
4.2. Most active in autoimmune dealmaking
4.3. List of most active dealmakers in autoimmune
4.4. Top autoimmune deals by value
Chapter 5 - Autoimmune deal contract document directory
5.1. Introduction
5.2. Autoimmune partnering deals where contract document available
Chapter 6 - Autoimmune dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by autoimmune therapeutic target
Companies Featured

• AbbVie
• Amgen
• AstraZeneca
• Biogen
• BioNTech
• Bristol-Myers Squibb
• CSL Behring
• Eli Lilly
• Gilead Sciences
• GlaxoSmithKline
• Johnson & Johnson
• Merck & Co.
• Moderna
• Novartis
• Pfizer
• Regeneron Pharmaceuticals
• Roche
• Sanofi
• Takeda Pharmaceutical
• Vertex Pharmaceuticals
• Alnylam Pharmaceuticals
• Argenx
• Astellas Pharma
• BeiGene
• Boehringer Ingelheim
• Blueprint Medicines
• CureVac
• Denali Therapeutics
• Galapagos
• Genmab
• Harmony Biosciences
• Horizon Therapeutics
• Incyte
• Kiniksa Pharmaceuticals
• Kyowa Kirin
• MeiraGTx
• Mirati Therapeutics
• Natera
• Neurocrine Biosciences
• Otsuka Pharmaceutical
• Royalty Pharma
• Sarepta Therapeutics
• Seattle Genetics
• Straumann Holding
• Sutro Biopharma
• UCB
• Ultragenyx Pharmaceutical
• Viatris
• Wuxi AppTec
• Zai Lab

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN19112025004107003653ID1110368292